Gunderson Dettmer represented client Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, in its research collaboration and license agreement with Janssen Biotech, Inc.

In the announcement of the transaction president and CEO of Xencor Bassil Dahiyat, Ph.D said, “The ability to study combinations of therapies from both companies’ prostate cancer portfolios leverages Xencor’s broad clinical pipeline and the leading prostate cancer therapeutics portfolio at Janssen. This collaboration with Janssen expands the use of our CD28 platform and complements our first wholly owned internal candidate, a B7-H3 x CD28 bispecific antibody designed to treat a range of solid tumors, which is currently advancing through preclinical development.”

The Gunderson deal team was led by Brendan McCarthy and included Brittany Nicely.